M032 + PEMBROLIZUMAB for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Oct 2021: Trial registered, NCT05084430
  2. 25 Feb 2022: Trial started, NCT05084430

The trials

NCT05084430: Study of Pembrolizumab and M032 (NSC 733972)

State
Under way
Phase
Phase 1 and Phase 2
People
28 planned
Started
25 Feb 2022
Primary completion
1 Mar 2027
Arms
Recurrent MG, Newly Diagnosed MG
Results
None posted
  1. 19 Oct 2021: Trial registered
  2. 25 Feb 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.